High cholesterol is a pervasive health concern with significant implications for cardiovascular health. Elevated levels of cholesterol in the bloodstream contribute to the development of atherosclerosis, thereby increasing the risk of heart disease and stroke – two leading causes of death in the United States. In addressing this widespread issue, statins have emerged as pivotal medications in the management of high cholesterol and the prevention of cardiovascular disease.
Widely prescribed for their cholesterol-lowering effects, statins play a crucial role in reducing cardiovascular risk. However, this therapeutic landscape is nuanced, requiring a thorough exploration of both the benefits and potential side effects of statin therapy. This discussion aims to provide insights into the multifaceted aspects of statin use, considering their effectiveness in cholesterol management and the imperative need to balance their advantages with a careful awareness of associated risks.
[signup]
Understanding Cholesterol and Its Impact on Health
Cholesterol is a waxy, fat-like substance found naturally in certain foods and endogenously made by the liver. Cholesterol is required by the body to make cell membranes, hormones, and vitamin D. Because cholesterol is a lipid, it cannot dissolve in water and, therefore, must be transported throughout the body on lipoproteins. Two main lipoproteins garner attention in the realm of cholesterol and cardiovascular health: low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL transports cholesterol from the liver to cells throughout the body. HDL scavenges excess cholesterol in the bloodstream and transports it back to the liver to be excreted from the body. (26)
LDL cholesterol (LDL-C) is the cholesterol carried on low-density lipoproteins. LDL-C makes up most of the body's cholesterol and is called "bad cholesterol" because high levels increase an individual's risk for atherosclerosis and cardiovascular disease. LDL contributes to atherosclerosis through a series of interconnected processes within the arterial wall. When endothelial damage occurs (such as by smoking or high blood pressure), LDL infiltrates the arterial intima and undergoes oxidative modifications, becoming oxidized LDL. This triggers an immune response, recruiting monocytes that differentiate into macrophages and engulf oxidized LDL, forming foam cells. The accumulation of foam cells leads to the development of fatty streaks, which are early atherosclerotic lesions. Foam cells perpetuate inflammation by releasing pro-inflammatory cytokines, further promoting plaque formation and progression. The chronic inflammatory state and continuous influx of LDL contribute to the thickening and hardening of arterial walls, increasing the risk of cardiovascular events. (32)
Conversely, HDL cholesterol (HDL-C), referred to as the "good" cholesterol, is the fraction of cholesterol carried through the body on high-density lipoproteins. Higher levels of HDL are associated with a lower risk of heart disease.
Statins: Mechanism of Action
Statin medications are a class of drugs known for their efficacy in managing high cholesterol and reducing cardiovascular risk. The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) guidelines emphasize statin medications as a first-line pharmacotherapy recommendation for managing dyslipidemia and reducing cardiovascular risk. These guidelines recommend statin therapy based on an individual's atherosclerotic cardiovascular disease (ASCVD) risk. Specifically, statins are recommended for individuals with clinical ASCVD, individuals with primary elevations of LDL-C levels of 190 mg/dL or higher, and those aged 40-75 years with diabetes and an LDL-C level between 70-189 mg/dL, depending on their ASCVD risk profile. Additionally, statins are advised for individuals aged 40-75 years without diabetes who have an LDL-C level between 70-189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher.
Cholesterol synthesis is a complex four-stage process that begins with acetyl-CoA and ends with the formation of cholesterol. The rate-limiting step of cholesterol biosynthesis is the conversion of HMG-CoA to mevalonate, catalyzed by the enzyme HMG-CoA reductase. (17) Statins act as competitive inhibitors of HMG-CoA reductase. By binding to the enzyme's active site, statins impede its function, thereby reducing HMG-CoA conversion to mevalonate. This inhibition not only decreases cholesterol synthesis but also leads to an upregulation of hepatic LDL receptors. The increased expression of LDL receptors enhances the clearance of circulating LDL-C from the bloodstream, significantly reducing LDL-C levels. Moreover, the inhibition of HMG-CoA reductase by statins triggers a cascade of events, ultimately contributing to the modulation of intracellular signaling pathways and anti-inflammatory effects. (40)
Using a maximally tolerated high-intensity statin can reduce LDL-C levels by 50% or more. Beyond LDL-C reduction, statins have also been associated with modest increases in HDL-C by 3-15%. This is likely linked to an indirect inhibition of CETP (cholesteryl ester transfer protein). CETP plays a role in lipid metabolism by facilitating the transfer of cholesteryl esters from HDL particles to other lipoproteins, such as LDL. As statins decrease LDL-C levels, there is a subsequent reduction in the availability of cholesteryl esters for transfer by CETP. This alteration in substrate availability may reduce CETP-mediated cholesteryl ester transfer from HDL to other lipoprotein particles. Consequently, there is an increase in the size and cholesterol content of HDL particles. (31)
Benefits of Statin Therapy
Numerous studies provide robust evidence supporting the cholesterol-lowering effects of statins. Randomized controlled trials have consistently demonstrated a significant reduction in LDL-C levels with statin therapy, establishing their role in primary and secondary prevention of cardiovascular events.
The Heart Protection Study (HPS) was a landmark randomized controlled trial designed to evaluate the efficacy of statin therapy in preventing major vascular events in individuals at high risk for cardiovascular disease. Conducted between 1994 and 2002, the study enrolled over 20,000 participants with pre-existing vascular disease or diabetes, assessing the impact of simvastatin, a statin, on cardiovascular outcomes. The trial utilized a double-blind, placebo-controlled design, where participants were randomly assigned to receive either 40 mg of simvastatin daily or a matching placebo. The results of the HPS trial demonstrated a significant reduction in major vascular events, including myocardial infarction, stroke, and coronary revascularization, among the group receiving simvastatin. The study's findings were pivotal in establishing the efficacy of statins in a broad population at high risk for cardiovascular events, providing robust evidence for the benefits of statin therapy in both primary and secondary prevention. The HPS trial played a crucial role in shaping contemporary guidelines for lipid-lowering therapy and contributed substantially to our understanding of the substantial impact of statins on reducing cardiovascular morbidity and mortality. (23)
The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial was conducted to assess the efficacy of rosuvastatin in preventing cardiovascular events in individuals with elevated high-sensitivity C-reactive protein (hs-CRP) levels but low or normal levels of LDL-C. The trial, initiated in 2003 and completed in 2008, employed a randomized, double-blind, placebo-controlled design, enrolling over 17,000 participants. The results of the JUPITER trial demonstrated a remarkable reduction in the incidence of major cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, among those receiving rosuvastatin compared to the placebo group. Notably, the trial highlighted the potential benefit of statin therapy in a specific population with elevated inflammatory markers but without hyperlipidemia. The conclusions drawn from JUPITER contributed to a paradigm shift in cardiovascular risk assessment, emphasizing the importance of considering inflammation as a critical factor in identifying individuals who could benefit from statin therapy for primary prevention, irrespective of traditional lipid levels. (39)
Common Side Effects of Statins
Myopathy (muscle pain) is one of the most common associated side effects associated with statin use. Statins deplete coenzyme Q10 (CoQ10), an important cofactor for mitochondrial function and energy production in muscle cells. Statins can also induce spontaneous and irregular leaks of calcium from storage compartments within muscle cells, disrupting the usual coordinated releases that trigger muscle contractions. This unregulated calcium leakage can potentially damage muscle cells, resulting in muscle pain and weakness.
Hydrophilic statins like pravastatin and rosuvastatin generally have a lower propensity for myopathy than their lipophilic counterparts, such as simvastatin and atorvastatin. This discrepancy is attributed to differences in their pharmacokinetics and muscle tissue penetration. (41)
Interestingly, there appears to be a nocebo effect associated with perceived muscle pain from statins, wherein individuals with negative expectations about the medication report experiencing the potential side effect at higher rates than the actual risk. The genuine risk of developing statin-induced muscle pain is around 5% or less. However, studies reveal that nearly 30% of individuals ceased statin use due to muscle aches, even when unknowingly taking a placebo. (30)
Statin therapy has also increased liver enzymes, signaling inflammation, in 1-3% of patients. This is usually dose-dependent and occurs within the first three months of statin therapy. Discontinuation of the statin typically results in the normalization of liver function tests. (36)
Managing Statin Side Effects
The side effects of statin medications can be prevented and managed through various strategies. Doctors often initiate a statin at a lower dose and gradually titrate the dose upwards. This allows patients to acclimate to the medication and potentially mitigates unwanted side effects.
For patients who do not tolerate initial statin therapy, switching to a different statin type is recommended, particularly favoring hydrophilic statins like pravastatin and rosuvastatin over their lipophilic counterparts. Intolerance to one statin medication does not translate to intolerance to all. The incidence of myopathy is highest with simvastatin 40 mg (50%) and lowest with Fluvastatin XL 80 mg (8%). According to one study, over 90% of individuals who ceased statin treatment due to an adverse event could be successfully rechallenged with a different statin (37).
Addressing potential nutrient deficiencies is also crucial to preventing statin intolerance. Randomized controlled trials have demonstrated that statins reduce circulating CoQ10 in cardiac and skeletal muscle by 16-54%. CoQ10 coadministration with statin therapy may ameliorate statin-associated muscle symptoms, including muscle pain, weakness, cramps, and fatigue. Studies have effectively dosed CoQ10 in doses ranging from 100-600 mg/day for 1-3 months. (35)
Low vitamin D status has emerged as a modifiable risk factor for statin intolerance, offering a promising avenue for intervention. Research suggests that individuals with inadequate vitamin D levels (particularly when less than 20 ng/mL) may be more susceptible to experiencing statin-associated myopathy. Studies have indicated that when concurrently administered with statins, vitamin D supplementation can potentially reduce the incidence and severity of myopathy. The mechanisms underlying this protective effect are not fully elucidated but may involve the role of vitamin D in muscle function, inflammation modulation, and cellular repair processes. (37, 38)
Statins and Lifestyle Modifications
Lifestyle modifications play a pivotal role in conjunction with statin therapy for effectively managing high cholesterol levels. Even when statin therapy is indicated for treating high cholesterol, lifestyle changes serve as the first-line treatment.
Diet for High Cholesterol
A heart-healthy diet is rich in fruits, vegetables, whole grains, and lean proteins. The Mediterranean diet is one such example. A 2017 study found that adherence to the Mediterranean diet emphasizing virgin olive oil decreased LDL-C in people at high risk for cardiovascular disease. Another study published in 2020 found that adherence to a diet combining the principles of the Portfolio and Mediterranean diets reduced LDL-C by 25%.
According to the AHA, the best way to lower cholesterol is by reducing saturated and trans fats. They recommend limiting saturated fats to less than 6% of daily calories and eliminating all trans fats from the diet. (34)
People aiming to treat high cholesterol should also focus on eating at least five servings of fruits and vegetables daily. Compared to those who eat two servings, people who eat five servings daily have a significantly lower risk of cardiovascular and all-cause mortality. (21) Fruits and vegetables are rich in soluble fiber and phytosterols, which bind cholesterol in the digestive tract to reduce intestinal absorption and increase excretion from the body (11).
Exercise for High Cholesterol
A sedentary lifestyle is linked to lower levels of HDL-C, which means fewer HDL particles are available to remove excess LDL-C from the arteries. Research demonstrates a dose-response relationship between increases in physical activity and improvements in lipid profiles – namely, elevations in HDL-C and reductions in total cholesterol and LDL-C. Treatment guidelines for high cholesterol state that adults should engage in at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity physical activity weekly.
Smoking Cessation for High Cholesterol
Smoking is a major modifiable risk factor for cardiovascular diseases, exerting a profound impact on cardiovascular health. The harmful substances present in tobacco smoke, such as nicotine and carbon monoxide, contribute to the development and progression of various cardiovascular conditions. Smoking is a significant contributor to atherosclerosis, increasing the risk of heart attacks and strokes. Moreover, smoking adversely affects blood pressure, cholesterol levels, and the overall function of the cardiovascular system. (9, 34)
Patients who quit smoking have measurable increases in HDL-C and total HDL particle number. Within a year of smoking cessation, the risk of heart attack drops dramatically. Within five years of quitting, smokers lower their risk of stroke to about that of a person who has never smoked. (9)
Controversies and Considerations in Statin Use
The use of statins has been subject to ongoing debates and considerations that warrant careful examination. One problem at the forefront of statin use is statin intolerance, which is the inability to tolerate at least two statins. Newer nonstatin medications have been developed for this population to effectively circumvent the problem of pharmacotherapy noncompliance due to adverse effects.
Another area of debate surrounds the risk-benefit ratio of statin therapy in low-risk individuals. Low risk is defined by a 10-year ASCVD score of less than 10%. Conventional guidelines recommend the initiation of statin medications for individuals with a 10-year ASCVD risk score of 7.5% or higher. While statins indisputably benefit those with a history of cardiovascular events or high-risk profiles, their use in individuals with lower baseline risk remains a subject of discussion. Striking the right balance involves considering individualized risk assessments, particularly when primary prevention is the goal, and integrating lifestyle modifications as the first-line strategy.
The use of statins in the elderly is another complex area, with considerations regarding potential benefits and risks. Current research has not demonstrated a definitive impact of statins on cardiovascular outcomes among older adults lacking preexisting coronary artery disease (CAD) or significant risk factors. The U.S. Preventive Services Task Force guideline underscores the insufficient evidence to assess the balance of benefits and harms of statin use in individuals aged over 75 years without a history of stroke or heart attack. For those aged 65-75 years with one or more risk factors, the recommendation suggests selective prescription of statins for individuals possessing at least one risk factor and a 7.5-10% risk of experiencing a cardiovascular event within the next ten years. This selective approach balances potential benefits and risks based on individualized risk assessments. (25)
[signup]
Key Takeaways
Statins undoubtedly play a role in managing high cholesterol and mitigating cardiovascular risk. However, a nuanced perspective is essential, acknowledging potential side effects and needing a balanced approach that factors in individual patient characteristics. The decision to initiate statin therapy should be guided by a thorough evaluation of risks and benefits, considering patient-specific factors such as age, comorbidities, and lifestyle. Encouraging a personalized medicine approach, ongoing research is vital to refine our understanding of statin therapy, tailor interventions to individual needs, and optimize cardiovascular outcomes. In navigating the landscape of statin use, the call for continued investigation and a patient-centered approach is fundamental to ensure the optimal and safe utilization of these essential medications in cardiovascular disease prevention.
High cholesterol is a common health concern with important implications for cardiovascular health. Elevated levels of cholesterol in the bloodstream may contribute to the development of atherosclerosis, which can increase the risk of heart disease and stroke – two leading causes of death in the United States. In addressing this widespread issue, statins have emerged as important medications in the management of high cholesterol and the support of cardiovascular health.
Widely prescribed for their cholesterol-lowering effects, statins play a crucial role in supporting cardiovascular health. However, this therapeutic landscape is nuanced, requiring a thorough exploration of both the benefits and potential side effects of statin therapy. This discussion aims to provide insights into the multifaceted aspects of statin use, considering their effectiveness in cholesterol management and the need to balance their advantages with a careful awareness of associated risks.
[signup]
Understanding Cholesterol and Its Impact on Health
Cholesterol is a waxy, fat-like substance found naturally in certain foods and made by the liver. Cholesterol is required by the body to make cell membranes, hormones, and vitamin D. Because cholesterol is a lipid, it cannot dissolve in water and, therefore, must be transported throughout the body on lipoproteins. Two main lipoproteins garner attention in the realm of cholesterol and cardiovascular health: low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL transports cholesterol from the liver to cells throughout the body. HDL helps remove excess cholesterol in the bloodstream and transports it back to the liver to be excreted from the body. (26)
LDL cholesterol (LDL-C) is the cholesterol carried on low-density lipoproteins. LDL-C makes up most of the body's cholesterol and is often called "bad cholesterol" because high levels may increase an individual's risk for atherosclerosis and cardiovascular disease. LDL contributes to atherosclerosis through a series of interconnected processes within the arterial wall. When endothelial damage occurs (such as by smoking or high blood pressure), LDL infiltrates the arterial intima and undergoes oxidative modifications, becoming oxidized LDL. This triggers an immune response, recruiting monocytes that differentiate into macrophages and engulf oxidized LDL, forming foam cells. The accumulation of foam cells leads to the development of fatty streaks, which are early atherosclerotic lesions. Foam cells perpetuate inflammation by releasing pro-inflammatory cytokines, further promoting plaque formation and progression. The chronic inflammatory state and continuous influx of LDL contribute to the thickening and hardening of arterial walls, increasing the risk of cardiovascular events. (32)
Conversely, HDL cholesterol (HDL-C), often referred to as the "good" cholesterol, is the fraction of cholesterol carried through the body on high-density lipoproteins. Higher levels of HDL are associated with a lower risk of heart disease.
Statins: Mechanism of Action
Statin medications are a class of drugs known for their efficacy in managing high cholesterol and supporting cardiovascular health. The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) guidelines emphasize statin medications as a first-line pharmacotherapy recommendation for managing dyslipidemia and supporting cardiovascular health. These guidelines recommend statin therapy based on an individual's atherosclerotic cardiovascular disease (ASCVD) risk. Specifically, statins are recommended for individuals with clinical ASCVD, individuals with primary elevations of LDL-C levels of 190 mg/dL or higher, and those aged 40-75 years with diabetes and an LDL-C level between 70-189 mg/dL, depending on their ASCVD risk profile. Additionally, statins are advised for individuals aged 40-75 years without diabetes who have an LDL-C level between 70-189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher.
Cholesterol synthesis is a complex four-stage process that begins with acetyl-CoA and ends with the formation of cholesterol. The rate-limiting step of cholesterol biosynthesis is the conversion of HMG-CoA to mevalonate, catalyzed by the enzyme HMG-CoA reductase. (17) Statins act as competitive inhibitors of HMG-CoA reductase. By binding to the enzyme's active site, statins impede its function, thereby reducing HMG-CoA conversion to mevalonate. This inhibition not only decreases cholesterol synthesis but also leads to an upregulation of hepatic LDL receptors. The increased expression of LDL receptors enhances the clearance of circulating LDL-C from the bloodstream, significantly reducing LDL-C levels. Moreover, the inhibition of HMG-CoA reductase by statins triggers a cascade of events, ultimately contributing to the modulation of intracellular signaling pathways and anti-inflammatory effects. (40)
Using a maximally tolerated high-intensity statin can reduce LDL-C levels by 50% or more. Beyond LDL-C reduction, statins have also been associated with modest increases in HDL-C by 3-15%. This is likely linked to an indirect inhibition of CETP (cholesteryl ester transfer protein). CETP plays a role in lipid metabolism by facilitating the transfer of cholesteryl esters from HDL particles to other lipoproteins, such as LDL. As statins decrease LDL-C levels, there is a subsequent reduction in the availability of cholesteryl esters for transfer by CETP. This alteration in substrate availability may reduce CETP-mediated cholesteryl ester transfer from HDL to other lipoprotein particles. Consequently, there is an increase in the size and cholesterol content of HDL particles. (31)
Benefits of Statin Therapy
Numerous studies provide robust evidence supporting the cholesterol-lowering effects of statins. Randomized controlled trials have consistently demonstrated a significant reduction in LDL-C levels with statin therapy, establishing their role in primary and secondary prevention of cardiovascular events.
The Heart Protection Study (HPS) was a landmark randomized controlled trial designed to evaluate the efficacy of statin therapy in supporting cardiovascular health in individuals at high risk for cardiovascular disease. Conducted between 1994 and 2002, the study enrolled over 20,000 participants with pre-existing vascular disease or diabetes, assessing the impact of simvastatin, a statin, on cardiovascular outcomes. The trial utilized a double-blind, placebo-controlled design, where participants were randomly assigned to receive either 40 mg of simvastatin daily or a matching placebo. The results of the HPS trial demonstrated a significant reduction in major vascular events, including myocardial infarction, stroke, and coronary revascularization, among the group receiving simvastatin. The study's findings were pivotal in establishing the efficacy of statins in a broad population at high risk for cardiovascular events, providing robust evidence for the benefits of statin therapy in both primary and secondary prevention. The HPS trial played a crucial role in shaping contemporary guidelines for lipid-lowering therapy and contributed substantially to our understanding of the substantial impact of statins on reducing cardiovascular morbidity and mortality. (23)
The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial was conducted to assess the efficacy of rosuvastatin in supporting cardiovascular health in individuals with elevated high-sensitivity C-reactive protein (hs-CRP) levels but low or normal levels of LDL-C. The trial, initiated in 2003 and completed in 2008, employed a randomized, double-blind, placebo-controlled design, enrolling over 17,000 participants. The results of the JUPITER trial demonstrated a remarkable reduction in the incidence of major cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, among those receiving rosuvastatin compared to the placebo group. Notably, the trial highlighted the potential benefit of statin therapy in a specific population with elevated inflammatory markers but without hyperlipidemia. The conclusions drawn from JUPITER contributed to a paradigm shift in cardiovascular risk assessment, emphasizing the importance of considering inflammation as a critical factor in identifying individuals who could benefit from statin therapy for primary prevention, irrespective of traditional lipid levels. (39)
Common Side Effects of Statins
Myopathy (muscle pain) is one of the most common associated side effects associated with statin use. Statins may affect coenzyme Q10 (CoQ10), an important cofactor for mitochondrial function and energy production in muscle cells. Statins can also induce spontaneous and irregular leaks of calcium from storage compartments within muscle cells, disrupting the usual coordinated releases that trigger muscle contractions. This unregulated calcium leakage can potentially affect muscle cells, resulting in muscle pain and weakness.
Hydrophilic statins like pravastatin and rosuvastatin generally have a lower propensity for myopathy than their lipophilic counterparts, such as simvastatin and atorvastatin. This discrepancy is attributed to differences in their pharmacokinetics and muscle tissue penetration. (41)
Interestingly, there appears to be a nocebo effect associated with perceived muscle pain from statins, wherein individuals with negative expectations about the medication report experiencing the potential side effect at higher rates than the actual risk. The genuine risk of developing statin-associated muscle pain is around 5% or less. However, studies reveal that nearly 30% of individuals ceased statin use due to muscle aches, even when unknowingly taking a placebo. (30)
Statin therapy has also been associated with increased liver enzymes, signaling inflammation, in 1-3% of patients. This is usually dose-dependent and occurs within the first three months of statin therapy. Discontinuation of the statin typically results in the normalization of liver function tests. (36)
Managing Statin Side Effects
The side effects of statin medications can be managed through various strategies. Doctors often initiate a statin at a lower dose and gradually increase the dose. This allows patients to acclimate to the medication and potentially mitigates unwanted side effects.
For patients who do not tolerate initial statin therapy, switching to a different statin type is an option, particularly favoring hydrophilic statins like pravastatin and rosuvastatin over their lipophilic counterparts. Intolerance to one statin medication does not translate to intolerance to all. The incidence of myopathy is highest with simvastatin 40 mg (50%) and lowest with Fluvastatin XL 80 mg (8%). According to one study, over 90% of individuals who ceased statin treatment due to an adverse event could be successfully rechallenged with a different statin (37).
Addressing potential nutrient deficiencies is also crucial to managing statin intolerance. Randomized controlled trials have demonstrated that statins may reduce circulating CoQ10 in cardiac and skeletal muscle by 16-54%. CoQ10 coadministration with statin therapy may help with statin-associated muscle symptoms, including muscle pain, weakness, cramps, and fatigue. Studies have effectively dosed CoQ10 in doses ranging from 100-600 mg/day for 1-3 months. (35)
Low vitamin D status has emerged as a modifiable factor for statin intolerance, offering a promising avenue for intervention. Research suggests that individuals with inadequate vitamin D levels (particularly when less than 20 ng/mL) may be more susceptible to experiencing statin-associated myopathy. Studies have indicated that when concurrently administered with statins, vitamin D supplementation can potentially reduce the incidence and severity of myopathy. The mechanisms underlying this protective effect are not fully elucidated but may involve the role of vitamin D in muscle function, inflammation modulation, and cellular repair processes. (37, 38)
Statins and Lifestyle Modifications
Lifestyle modifications play a pivotal role in conjunction with statin therapy for effectively managing high cholesterol levels. Even when statin therapy is indicated for managing high cholesterol, lifestyle changes serve as the first-line approach.
Diet for High Cholesterol
A heart-healthy diet is rich in fruits, vegetables, whole grains, and lean proteins. The Mediterranean diet is one such example. A 2017 study found that adherence to the Mediterranean diet emphasizing virgin olive oil was associated with decreased LDL-C in people at high risk for cardiovascular disease. Another study published in 2020 found that adherence to a diet combining the principles of the Portfolio and Mediterranean diets was associated with a reduction in LDL-C by 25%.
According to the AHA, one way to manage cholesterol is by reducing saturated and trans fats. They recommend limiting saturated fats to less than 6% of daily calories and eliminating all trans fats from the diet. (34)
People aiming to manage high cholesterol should also focus on eating at least five servings of fruits and vegetables daily. Compared to those who eat two servings, people who eat five servings daily have a significantly lower risk of cardiovascular and all-cause mortality. (21) Fruits and vegetables are rich in soluble fiber and phytosterols, which bind cholesterol in the digestive tract to reduce intestinal absorption and increase excretion from the body (11).
Exercise for High Cholesterol
A sedentary lifestyle is linked to lower levels of HDL-C, which means fewer HDL particles are available to help remove excess LDL-C from the arteries. Research demonstrates a dose-response relationship between increases in physical activity and improvements in lipid profiles – namely, elevations in HDL-C and reductions in total cholesterol and LDL-C. Treatment guidelines for high cholesterol state that adults should engage in at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity physical activity weekly.
Smoking Cessation for High Cholesterol
Smoking is a major modifiable risk factor for cardiovascular diseases, exerting a profound impact on cardiovascular health. The harmful substances present in tobacco smoke, such as nicotine and carbon monoxide, contribute to the development and progression of various cardiovascular conditions. Smoking is a significant contributor to atherosclerosis, increasing the risk of heart attacks and strokes. Moreover, smoking adversely affects blood pressure, cholesterol levels, and the overall function of the cardiovascular system. (9, 34)
Patients who quit smoking may experience measurable increases in HDL-C and total HDL particle number. Within a year of smoking cessation, the risk of heart attack drops dramatically. Within five years of quitting, smokers may lower their risk of stroke to about that of a person who has never smoked. (9)
Controversies and Considerations in Statin Use
The use of statins has been subject to ongoing debates and considerations that warrant careful examination. One problem at the forefront of statin use is statin intolerance, which is the inability to tolerate at least two statins. Newer nonstatin medications have been developed for this population to effectively circumvent the problem of pharmacotherapy noncompliance due to adverse effects.
Another area of debate surrounds the risk-benefit ratio of statin therapy in low-risk individuals. Low risk is defined by a 10-year ASCVD score of less than 10%. Conventional guidelines recommend the initiation of statin medications for individuals with a 10-year ASCVD risk score of 7.5% or higher. While statins indisputably benefit those with a history of cardiovascular events or high-risk profiles, their use in individuals with lower baseline risk remains a subject of discussion. Striking the right balance involves considering individualized risk assessments, particularly when primary prevention is the goal, and integrating lifestyle modifications as the first-line strategy.
The use of statins in the elderly is another complex area, with considerations regarding potential benefits and risks. Current research has not demonstrated a definitive impact of statins on cardiovascular outcomes among older adults lacking preexisting coronary artery disease (CAD) or significant risk factors. The U.S. Preventive Services Task Force guideline underscores the insufficient evidence to assess the balance of benefits and harms of statin use in individuals aged over 75 years without a history of stroke or heart attack. For those aged 65-75 years with one or more risk factors, the recommendation suggests selective prescription of statins for individuals possessing at least one risk factor and a 7.5-10% risk of experiencing a cardiovascular event within the next ten years. This selective approach balances potential benefits and risks based on individualized risk assessments. (25)
[signup]
Key Takeaways
Statins undoubtedly play a role in managing high cholesterol and supporting cardiovascular health. However, a nuanced perspective is essential, acknowledging potential side effects and needing a balanced approach that factors in individual patient characteristics. The decision to initiate statin therapy should be guided by a thorough evaluation of risks and benefits, considering patient-specific factors such as age, comorbidities, and lifestyle. Encouraging a personalized medicine approach, ongoing research is vital to refine our understanding of statin therapy, tailor interventions to individual needs, and optimize cardiovascular outcomes. In navigating the landscape of statin use, the call for continued investigation and a patient-centered approach is fundamental to ensure the optimal and safe utilization of these essential medications in cardiovascular health support.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.
Abed, W., Abujbara, M., Batieha, A., et al. (2022). Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. Annals of Medicine and Surgery, 74, 103304. https://doi.org/10.1016/j.amsu.2022.103304
Abramson, J. D., Rosenberg, H. G., Jewell, N., et al. (2013). Should people at low risk of cardiovascular disease take a statin? BMJ, 347(oct22 3), f6123–f6123. https://www.bmj.com/content/348/bmj.g3329
Ali, K. M., Wonnerth, A., Huber, K., et al. (2012). Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities. British Journal of Pharmacology, 167(6), 1177–1194. https://doi.org/10.1111/j.1476-5381.2012.02081.x
American Heart Association. (2018). Cholesterol Management Guide For Healthcare Professionals. https://professional.heart.org/-/media/Files/Health-Topics/Cholesterol/Cholesterol-guide-for-HC-Practitioners-English.pdf
Ferro, Y., Mazza, E., Salvati, M., et al. (2020). Effects of a Portfolio-Mediterranean Diet and a Mediterranean Diet with or without a Sterol-Enriched Yogurt in Individuals with Hypercholesterolemia. Endocrinology and Metabolism, 35(2), 298–307. https://doi.org/10.3803/enm.2020.35.2.298
Gepner, A. D., Piper, M. E., Johnson, H. M., et al. (2011). Effects of smoking and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial. American Heart Journal, 161(1), 145–151. https://doi.org/10.1016/j.ahj.2010.09.023
Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2018). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation, 139(25). https://doi.org/10.1161/cir.0000000000000625
Heart Protection Study Collaborative Group. (2007). Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery, 45(4), 645-654.e1. https://doi.org/10.1016/j.jvs.2006.12.054
Hernáez, Á., Castañer, O., Goday, A., et al. (2017). The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk individuals: a randomized controlled trial. Molecular Nutrition & Food Research, 61(9), 1601015. https://doi.org/10.1002/mnfr.201601015
da Silva Maciel, E., Silva, B. K. R., dos Santos Figueiredo, F. W., et al. (2022). Physical inactivity level and lipid profile in traditional communities in the Legal Amazon: a cross-sectional study. BMC Public Health, 22(1). https://doi.org/10.1186/s12889-022-12973-9
Mann, S., Beedie, C., & Jimenez, A. (2013). Differential Effects of Aerobic Exercise, Resistance Training and Combined Exercise Modalities on Cholesterol and the Lipid Profile: Review, Synthesis and Recommendations. Sports Medicine, 44(2), 211–221. https://doi.org/10.1007/s40279-013-0110-5
McTaggart, F., & Jones, P. (2008). Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. Cardiovascular Drugs and Therapy, 22(4), 321–338. https://doi.org/10.1007/s10557-008-6113-z
Qu, H., Guo, M., Chai, H., et al. (2018). Effects of Coenzyme Q10 on Statin‐Induced Myopathy: An Updated Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 7(19). https://doi.org/10.1161/jaha.118.009835
Ramkumar, S., Raghunath, A., & Raghunath, S. (2016). Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiologica Sinica, 32(6), 631–639. https://doi.org/10.6515/ACS20160611A
Reston, J. T., Buelt, A., Donahue, M. P., et al. (2020). Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease. Annals of Internal Medicine, 173(10), 806–812. https://doi.org/10.7326/m20-4680
Riche, K. D., Arnall, J., Rieser, K., et al. (2016). Impact of vitamin D status on statin-induced myopathy. Journal of Clinical & Translational Endocrinology, 6, 56–59. https://doi.org/10.1016/j.jcte.2016.11.002
Ridker, P. M., Danielson, E., Fonseca, F. A. H., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359(21), 2195–2207. https://doi.org/10.1056/NEJMoa0807646
Vinci, P., Panizon, E., Tosoni, L. M., et al. (2021). Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences, 22(21), 11687. https://doi.org/10.3390/ijms222111687
Virani, S. S. (2013). Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Texas Heart Institute Journal, 40(3), 288–289. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709236/
Wong, N. D., Budoff, M. J., Ferdinand, K., et al. (2022). Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 10, 100335. https://doi.org/10.1016/j.ajpc.2022.100335
Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.
Hey practitioners! 👋 Join Dr. Terry Wahls for a 3-week bootcamp on integrating functional medicine into conventional practice, focusing on complex cases like Multiple Sclerosis. Learn to analyze labs through a functional lens, perform nutrition-focused physical exams, and develop personalized care strategies. Register Here.
%201.svg){kind=logo}
